Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

For many years, mCRPC was considered to confer a terminal prognosis, with a median survival of 12 months from development of castrate resistance. [2] However, the advent of several new agents has ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

A new FDA approval has brought a renewed sense of hope as an innovative new treatment approach is now available to ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Janux Therapeutics' lead drug, JANX007, shows promising prostate cancer results with no serious side effects. Find out why ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

Men with metastatic castration-resistant prostate cancer (mCRPC) lived 19-20 months whether they received docetaxel plus pembrolizumab (Keytruda) or placebo. The addition of pembrolizumab did not ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s NVS Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of patients ...